BioSpace News Archive

The FDA granted argenx Priority Review status for the company’s BLA for SC efgartigimod for generalized myasthenia gravis.

Following a request from the FDA, GSK is withdrawing its multiple myeloma drug Blenrep from the U.S. market while continuing to push other combination trial programs.

Merck is eyeing another major label expansion for its flagship anti-PD-1 therapy Keytruda following an interim analysis of KEYNOTE-859 trial.

Kinarus Therapeutics Holding AG announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases “ covering its therapeutic candidate KIN001 in age-related macular degeneration.

argenx SE announced the U.S. Food and Drug Administration has accepted for priority review a Biologics License Application for SC efgartigimod for the treatment of adult patients with generalized myasthenia gravis.

Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc.

InnoCare Pharma announced that HIBRUKA has been approved by the Health Sciences Authority of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Accure Acne, Inc. (www.accureacne.com), a pioneer in the development of innovative solutions for the treatment of acne, announced today it has received FDA clearance for its Accure Laser™ System to treat mild to severe inflammatory acne vulgaris.

Turbine, a company developing a cell behavior simulation platform, announced the closing of a €20 million Series A financing round.

With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield.